| Mechanisms and predictors of mitral regurgitation after high-risk myocardial infarction. | |
| | |
MedLine Citation:
|
PMID: 22305962 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Mitral regurgitation (MR) has been associated with adverse outcomes after myocardial infarction (MI). Without structural valve disease, functional MR has been related to left ventricular (LV) remodeling and geometric deformation of the mitral apparatus. The aims of this study were to elucidate the mechanistic components of MR after high-risk MI and to identify predictors of MR progression during follow-up. METHODS: The Valsartan in Acute Myocardial Infarction Echo substudy prospectively enrolled 610 patients with LV dysfunction, heart failure, or both after MI. MR at baseline, 1 month, and 20 months was quantified by mapping jet expansion in the left atrium in 341 patients with good-quality echocardiograms. Indices of LV remodeling, left atrial size, and diastolic function and parameters of mitral valve deformation, including tenting area, coaptation depth, anterior leaflet concavity, annular diameters, and contractility, were assessed and related to baseline MR. The progression of MR was further analyzed, and predictors of worsening among the baseline characteristics were identified. RESULTS: Tenting area, coaptation depth, annular dilatation, and left atrial size were all associated with the degree of baseline MR. Tenting area was the only significant and independent predictor of worsening MR; a tenting area of 4 cm(2) was a useful cutoff to identify worsening of MR after MI and moderate to severe MR after 20 months. CONCLUSIONS: Increased mitral tenting and larger mitral annular area are determinants of MR degree at baseline, and tenting area is an independent predictor of progression of MR after MI. Although LV remodeling itself contributes to ischemic MR, this influence is directly dependent on alterations in mitral geometry. |
| | |
Authors:
|
Alessandra Meris; Maria Amigoni; Anil Verma; Jens Jakob Thune; Lars Køber; Eric Velazquez; John J V McMurray; Marc A Pfeffer; Robert Califf; Robert A Levine; Scott D Solomon; |
Publication Detail:
|
Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't Date: 2012-02-04 |
Journal Detail:
|
Title: Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography Volume: 25 ISSN: 1097-6795 ISO Abbreviation: J Am Soc Echocardiogr Publication Date: 2012 May |
Date Detail:
|
Created Date: 2012-04-24 Completed Date: 2012-08-30 Revised Date: 2013-05-02 |
Medline Journal Info:
|
Nlm Unique ID: 8801388 Medline TA: J Am Soc Echocardiogr Country: United States |
Other Details:
|
Languages: eng Pagination: 535-42 Citation Subset: IM |
Copyright Information:
|
Copyright © 2012 American Society of Echocardiography. Published by Mosby, Inc. All rights reserved. |
Affiliation:
|
Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Age Factors Aged Angiotensin-Converting Enzyme Inhibitors / therapeutic use* Captopril / therapeutic use Disease Progression Echocardiography, Doppler, Color / methods* Electrocardiography / methods Female Follow-Up Studies Humans Male Middle Aged Mitral Valve Insufficiency / epidemiology, etiology, ultrasonography* Monitoring, Physiologic / methods Multivariate Analysis Myocardial Infarction / complications*, diagnosis, drug therapy* Predictive Value of Tests Prospective Studies ROC Curve Reference Values Reproducibility of Results Risk Assessment Severity of Illness Index Sex Factors Statistics, Nonparametric Stroke Volume / physiology Tetrazoles / therapeutic use Time Factors Valine / analogs & derivatives, therapeutic use Ventricular Dysfunction, Left / epidemiology, etiology, ultrasonography Ventricular Remodeling / physiology |
| Grant Support | |
ID/Acronym/Agency:
|
K24 HL067434/HL/NHLBI NIH HHS; R01 HL072265/HL/NHLBI NIH HHS; R01 HL109506/HL/NHLBI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Angiotensin-Converting Enzyme Inhibitors; 0/Tetrazoles; 137862-53-4/valsartan; 62571-86-2/Captopril; 7004-03-7/Valine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Susceptibility of the PER.C6 cell line for infection with clinical human respiratory syncytial virus...
Next Document: The innate immune response to products of phospholipid peroxidation.